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Abstract: A wide variety of peptides not only interact with the cell surface, but govern complex
signaling from inside the cell. This has been referred to as an “intracrine” action, and the orchestrating
molecules as “intracrines”. Here, we review the intracrine action of dynorphin B, a bioactive
end-product of the prodynorphin gene, on nuclear opioid receptors and nuclear protein kinase C
signaling to stimulate the transcription of a gene program of cardiogenesis. The ability of intracrine
dynorphin B to prime the transcription of its own coding gene in isolated nuclei is discussed
as a feed-forward loop of gene expression amplification and synchronization. We describe the
role of hyaluronan mixed esters of butyric and retinoic acids as synthetic intracrines, controlling
prodynorphin gene expression, cardiogenesis, and cardiac repair. We also discuss the increase in
prodynorphin gene transcription and intracellular dynorphin B afforded by electromagnetic fields in
stem cells, as a mechanism of cardiogenic signaling and enhancement in the yield of stem cell-derived
cardiomyocytes. We underline the possibility of using the diffusive features of physical energies to
modulate intracrinergic systems without the needs of viral vector-mediated gene transfer technologies,
and prompt the exploration of this hypothesis in the near future.
Keywords: stem cells; dynorphin B; prodynorphin gene; intracrine; nuclear opioid receptors;
transcription factors; cardiogenesis; cardiac regeneration; hyaluronan esters; electromagnetic fields
1. Introduction
Cell-to-cell communication is usually viewed as a signaling cross-talk between neighboring
cells, referred to as paracrine communication, or as a modality in which a given cell is able to
release signaling molecules that in turn bind receptors on that same cell, according to a so-called
autocrine communication.
In 1984, Re and Coworkers introduced the term intracrine, to define a peptide action within the
cell interiors, identifying a different route as compared to a peptide/hormone acting at the level of
cell-surface receptors [1,2]. An intracrine could, therefore, then be defined as an agonist, including
a hormone or other signaling peptides/proteins, controlling cellular dynamics from within the cell
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of synthesis, or inside a target cell after internalization [3,4]. The notion of intracrine physiology
grew up over time, generating novel perspectives in the way of conceiving intracellular trafficking
and cell signaling. A remarkably growing number of endogenous molecules have been added
to the intracrine list during the last few years, including hormones, cytokines, and many growth
factors, whose action was believed to occur only at the plasma membrane level [4,5]. A significant
breakthrough in the deployment of intracrine mechanisms came from the progressive awareness that
most of the signaling players are not acting as naked molecules, but they can be rather travelling
among and inside cells packaged within exosomes. The multifaceted content of these nanovesicles
can be poured inside the cells as “pocket-of-information” controlling nuclear trafficking, epigenetic
and transcriptional patterning. Consonant with this intriguing scenario, it is now evident that even
transcription factors, DNA binding proteins, and enzymes can be exchanged through the exosomal
route [6,7], and also likely through cellular nanotubes, a kind of nanostructures that are currently
emerging as an additional modality of inter-/intra-cellular spreading of biological information [8–10].
The existence of nuclear and/or other intracellular binding sites capable of unfolding the presence of
these molecules into concerted cell signaling pathways are now offering novel clues to reinterpret
the role of nanovesicular/nanotubular transport systems. Nonetheless, the intracrine world is posing
new challenges in deciphering the subtle line of demarcation between physiological and pathological
patterns (Figure 1).
Figure 1. Intracrine patterning. The figure depicts a scheme of intracrine signaling within the context
of intra- and extra-cellular communication via paracrine, autocrine, and exosomal routes. GA: Golgi
Apparatus; RE: Endoplasmic Reticulum; PS: Perinuclear Space; red shape: receptor; blue shape: signal.
Growing evidence has accumulated over recent years showing that the biological effect of
Angiotensin II on its target genes can be mediated by the interaction of Angiotensin II with intracellular
receptor types 1 and 2 (AT1 and AT2), associated with intracrine responses [11]. In human mesangial
cells both receptors were found in the nuclear membrane, and the addition of labeled Angiotensin II
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to isolated mesangial cell nuclei produced a fluorescence that could be inhibited by specific receptor
antagonists [11]. Cell exposure to high glucose, which stimulates endogenous intracellular Angiotensin
II synthesis was able to induce mesangial cell proliferation and overexpression of fibronectin even
in the presence of candesartan which prevents Angiotensin II internalization, therefore, indicating
an intracrine action of endogenous, high glucose-induced Angiotensin II, independent of cell surface
receptors [11].
Vascular endothelial growth factor (VEGF) is another peptide playing a remarkable role in
both somatic and stem cell dynamics. Hematopoietic stem cells (HSCs) express and secrete VEGF,
and during their development to megakaryocytes (MKs) the structurally related receptors VEGFR1,
VEGFR2, and VEGFR3 are expressed at a different developmental stage. VEGF has been shown to
act in an intracrine fashion to promote HSC survival and repopulation [12,13]. Moreover, VEGFR2
has been found in the nucleus of human erythroleukemia cells (HEL), with features of MKs, being
constitutively phosphorylated [14], and could be inhibited by internal VEGFR2-specific inhibitor, to
prevent constitutive activation of MAPK/ERK and PI3/AKT, therefore, leading to HEL apoptosis [14].
Conversely, extracellular acting anti VEGF monoclonal antibody only elicited a weak apoptotic
response [14]. These findings indicate: (1) The relevance of the intracrine pathway in HSC dynamics; (2)
the fact that autocrine/paracrine, and intracrine loops, as those mediated by VEGF, act by modulating
different stem cell functions and signaling pathways; (3) the complexity of the intracrine loops, and
that fact that a subtle demarcation line divides the beneficial effects of intracrine peptides from
the pathological outcomes resulting from malfunctioning of their related pathways. Accordingly,
VEGF-VEGFR intracrine signaling has been shown to be required for both normal endothelial cell
homeostasis and tumor-associated endothelial cell survival [15,16]. It has also been recently reported
that a dysregulation of intracrine VEGF-VEGFR axis within the control of apoptotic, survival, and
proliferation pathway may also lead to the survival and proliferation of unwanted cell types, as it
has been shown for colorectal cancer [17], as well as in normal and pathological (i.e., malignant)
developmental stages of MKs, and platelets [18–21].
The list of peptides acting not only in a paracrine/autocrine, but even intracrine fashion is fated to
grow exponentially, as shown by the dissection of the intracrine action of Fibroblast Growth Factor 1
(FGF1), a prototypic member in the FGFs family, whose intracrine modality of action has been shown
to be executed at nuclear level to induce neuronal differentiation and regulate stem cell response
to apoptosis. In this regard, the induction of mutation in specific domains of FGF1 has provided
remarkable insights in elucidating its nuclear pathways. Overall, there is now compelling indication
that future studies on the intracrine responses mediated by peptides subjected to targeted domain
mutations may provide significant breakthrough on how intracrine peptides may affect normal stem
cell differentiation, or they may be conversely responsible for malignant stem cell transformation,
tumor dissemination and resistance to radio- and chemo-therapy [22]. Akin to this perspective,
photo-releasable ligands [23], and caged ligands [24] are currently under development as additional
tools to study the intracrine signaling of various peptides in intact cells.
Compounding the complexity of intracrinergic systems, a novel cardiac intracrine mechanism
has been recently shown in the heart, where Angiotensin-(1–12), a newly uncovered angiotensinogen
derivative, is acting as the precursor of Angiotensin II, and a chymase rather than the Angiotensin
Converting Enzyme (ACE) is the main enzyme involved in the production of Angiotensin II from
Angiotensin-(1–12) [25]. It is now evident that the Angiotensin-(1–12)/chymase axis represents an
independent intracrinergic system accounting for major effects exerted by Angiotensin II in the
human heart, including trophic, contractile and rhythmic dynamics [25]. There is now evidence that
dysregulation of this intracrine axis may play a major role in the onset and progression of human heart
failure, as suggested by the finding that Angiotensin-(1–12) and chymase expression and activity are
both elevated in the heart of patients undergoing heart failure [25]. These findings, accounting for the
production of Angiotensin II independently from the circulatory Renin/Angiotensin System, may also
explain the shortcomings of ACE inhibition and Angiotensin receptor blockade in a consistent number
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of patients, who, differently from the one responding to this treatment, will remain at risk for heart
disease progression.
Within the context of the cardiovascular system, it is now emerging that intracrine physiology
may further unfold the basis for understanding the exchange of chemical signals between cardiac
cells. In these cells, the role of gap junctions in transferring chemical information can now be viewed
in close association with the intracellular action of different factors (hormones, regulatory peptides)
acting through an intracrine modality to affect cell volume and shape, chemical coupling and cardiac
energetics [26]. The intracrine view building around the heart may help to conceive this organ as
a metabolic syncytium, where glucose, nucleotides and hormones can be engaged in cell-to-cell
trafficking through gap junctions [26]. This view may help to provide a new vision on how cardiac
intracrine pathways may be part of a “fruitful” cooperative scenario under physiological conditions, or
they may undergo unbalanced interplay, drifting from cardiac physiology to cardiac pathological states.
On the basis of these premises, we here intended to review the experimental works that investigate
the intracrine role of Dynorphin B in stem and myocardial cells and the modulation/expression of this
endorphin following hyaluronan mixed esters of butyric and retinoic acids (HBR) or electromagnetic
energy administration. We retain that the study of intracrinergic pathways at the stem cell level may
help to understand the mechanisms of cardiogenesis better, and provide potential new strategies in
cardiac repair and regeneration.
2. Opioid Peptides and the Intracrine Regulation of Cellular Dynamics: A Pattern Highly
Oriented Towards Stem Cell Cardiogenesis
Opioid peptides (also referred to as endorphin peptides) are co-released with other
neurotransmitters from both sympathetic and parasympathetic nerve endings, acting at presynaptic
level to inhibit noradrenaline [27–29] or acetylcholine release [30–34]. It is now established that at
myocardial level endorphin peptides not only act by modulating the neurotransmitter release from
the nerve endings supplying the heart [35–39], but they can also directly act on specific receptors
that have been detected on myocardial cells. We provided evidence that among the three main
opioid receptors, µ, δ and κ, both δ- and κ-opioid receptors were expressed in the sarcolemma of
myocardial cells [40]. Moreover, a marked increase in selective agonist binding could be achieved
in the presence of the α-adrenoceptor agonist phenylephrine or with the β-adrenoceptor agonist
isoproterenol, indicating functional responsiveness of the identified binding sites. These observations
prompted us to hypothesize that opioid receptors may be involved in the regulation of myocardial cell
function. This perspective was then supported by a number of interrelated observations, showing that
in cardiac myocytes κ and δ opioid receptor stimulation: (1) Increased cytosolic pH and myofilament
responsiveness to Ca2; (2) affected phosphoinositide turnover by increasing the formation of both
inositol 1,4,5-trisphosphate (Ins(1,4,5)P3), and inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) [41];
and (3) affected contractile dynamics in cardiomyocytes, as well as Ca2+ release from an intracellular
pool in both cardiomyocytes and neurons [42,43]. These data, and other reports from studies showing
that endorphins affected the contractility in isolated rat hearts [44,45], in dog myocardium [46], or
cultured chick embryo heart cells [47,48], supported the notion that the myocardial cell could be
a direct target for the action of these peptides (Figure 2). Even more intriguingly, large amounts
of preproenkephalin mRNA, encoding for a peptide (preproenkephalin A), containing four copies
of [Met]enkephalin and one copy each of [Leu]enkephalin, [Met]enkephalin-Arg6-Gly7-Leu8, and
[Met]enkephalin-Arg6-Phe7, all mainly acting on δ opioid receptors, were initially detected in the
rat heart tissue [49,50], that was found to contain greater amounts of the coding mRNA than any
other rat tissue, including the brain [49]. Nevertheless, despite the large amounts of preproenkephalin
mRNA in the heart, the cardiac content of the opioid peptide (preproenkephalin A) was only 3% the
amount detected in the brain [49]. Concomitantly, remarkable amounts of prodynorphin-derived
peptides, which are encoded by the prodynorphin gene, and mainly act as endogenous κ opioid receptor
agonists, were found in human, rat, rabbit, and guinea-pig hearts [51]. These studies were conducted
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in multicellular preparations and could not discern the cell type responsible for the observed peptide
synthesis. These findings induced us to investigate whether the prodynorphin gene and its related
peptides may be expressed in the myocardial cell, and whether in the affirmative, the cardiac myocyte
itself may be considered not only a target, but a source for endorphin peptides. This hypothesis was
confirmed in subsequent studies showing that: (1) The prodynorphin gene was expressed in adult rat
ventricular cardiomyocytes [52]; (2) dynorphin B, a bioactive end-product of the gene, could be detected
both intracellularly and in the culture medium [52]; (3) the prodynorphin gene transcription, as well
as the amount of intracellular and secreted dynorphin B, were enhanced by cardiomyocyte exposure
to high potassium chloride (KCl) [52]; (4) the myocardial expression of the prodynorphin gene and
dynorphin B (both the intracellular and secreted peptide) could also be enhanced by cell exposure to
phorbol 12-myristate 13-acetate (PMA) through a mechanism depending upon the activation of nuclear
protein kinase C (PKC) [53]; (5) the transcription of the prodynorphin gene was increased both in nuclei
isolated from PMA-treated cardiomyocytes and in isolated myocardial nuclei directly treated with the
phorbol ester [53]; (6) both PKC-δ and –εwere expressed in isolated myocardial nuclei, and the PKC
inhibitor staurosporine abolished the increase in prodynorphin gene transcription elicited by the nuclear
exposure to PMA [53] (Table 1). An additional consequence of these findings was that they provided
the underpinning for the investigation of an intracellular modality of action of cardiac endorphins in
the regulation of myocardial cell dynamics. In 1998 we discovered the presence of κ-opioid receptors in
highly purified nuclei isolated from myocardial cells [54]. These studies revealed a significant increase
in the maximal binding capacity for a selective κ-opioid receptor ligand in myocardial nuclei that
had been isolated from BIO 14.6 cardiomyopathic hamsters, in comparison with nuclei obtained from
normal cardiomyocytes of the F1B strain. Interestingly, the exposure of nuclei isolated from normal
myocardial cells to dynorphin B, a natural agonist of κ-opioid receptors, remarkably enhanced the
transcription of the prodynorphin gene [54]. This transcriptional response was mediated by nuclear PKC
activation and occurred at a higher rate in nuclei obtained from cardiomyopathic myocytes than in
nuclei that had been isolated from normal cardiomyocytes [54]. These initial studies provided the first
evidence that a nuclear endorphinergic system was part of an intracrine loop involving a feed-forward
stimulation of dynorphin B on the transcription of its own coding gene, imparting features of long-lived
signaling and memory (Figure 2).
Table 1. Effects of different agents on cardiac function and commitment.
Stimulus Species Cell Type Biological Effects Ref.
KCl1 60 mM
(for 4 or 24 h of
treatment)
Rat VentricularCardiomyocytes
Increased expression of the prodynorphin gene
Increase of dynorphin B
At the intracellular level and in the culture medium
[52]
PMA2 100 nM







Activation of the nuclear protein kinases C-δ and -ε
Subsequent increased expression of the prodynorphin
gene
Increase of dynorphin B
At the intracellular level and in the culture medium
[53]
DMSO3 1%
(for 2 or 4 days of
treatment)
Mouse P19 ESCs4
Increased expression of the prodynorphin gene
Following an increase of GATA-4 and Nkx-2.5
expression
Increase of dynorphin B
At the intracellular level and in the culture medium
Counteracted by opioid receptor antagonism or
targeted inhibition of prodynorphin gene expression
[55]
1 Potassium chloride; 2 Phorbol 12-myristate 13-acetate; 3 dimethyl sulfoxide; 4 embryonic stem cells.
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Figure 2. Intracrine dynorphin B pathway in rat ventricular cardiomyocytes. Th figure represents a
virtual cell where different experimental evidence (detailed in the manuscript) is schematically shown.
SR: Sarcoplasmic reticulum; Ins(1,3,4,5)P4: Inositol 1,3,4,5-tetrakisphosphate; Ins(1,4,5)P3: Inositol
1,4,5-trisphosphate; PKC: Protein kinase C.
In subsequent studies, the prodynorphin gene and its bioactive end-product dynorphin B emerged
as major conductors of cardiogenesis in embryonic stem cells (ESCs) [55]. In pluripotent P19 cells, the
transcription of GATA-4 and Nkx-2.5, governing crucial developmental steps towards cardiogenesis,
was induced by cell exposure to dimethyl sulfoxide (DMSO), and was preceded by a marked increase
in prodynorphin gene expression. This transcriptional response was associated with a pronounced rise
in the intracellular level of dynorphin B, indicating the chance for an intracrine action of the peptide in
eliciting the cardiogenic process [55]. In DMSO treated cells, we also detected an increase of dynorphin
B in the culture medium, suggesting the establishment of an autocrine mechanism [55] (Table 1), as
we previously observed in cardiomyocytes of Syrian cardiomyopathic Hamsters [56–58], where a
specific κ-opioid receptor antagonist was able to counteract the spontaneous overexpression of the
prodynorphin gene and dynorphin B by interrupting an autocrine feed-forward loop sustained by the
secreted peptide [58]. Interestingly, even in the absence of DMSO, dynorphin B-conditioned medium
was able to trigger GATA-4 and Nkx-2.5 gene transcription, enhancing the gene and protein expression
of α-myosin heavy chain (α-MHC) and myosin light chain (MLC)-2V, two markers of terminal cardiac
differentiation [55]. A causal role of dynorphin B in ESC cardiogenesis was also inferred by the finding
that the differentiating effect of DMSO could be counteracted by opioid receptor antagonism or targeted
inhibition of prodynorphin gene expression [55]. These findings were further supported by the possibility
to create a cardiogenic stem cell line based upon lentiviral mediated overexpression of the prodynorphin
gene in mouse ESCs [59]. Lentiviral transduction enhanced the transcription of the cardiogenic genes
GATA-4 and Nkx-2.5, along with other markers of terminal differentiation, as α-sarcomeric actinin (SA),
cardiac L-type Ca2+ channel, connexin 43, and dramatically increased the yield of spontaneously beating
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ESC-derived cardiomyocytes [59]. A compelling evidence for a major role of an endorphinergic system
in cardiogenesis was provided by a number of interrelated findings showing that: (1) Endogenous
dynorphin B was essential in the cardiogenic process of GTR1 ESCs, a derivative of mouse R1 ES cells
bearing the puromycin resistance gene driven by the cardiomyocyte-specific α-MHC promoter [60];
(2) immunoreactive dynorphin B was faintly detected in undifferentiated ESCs, while being highly
enhanced inside ESC-derived cardiomyocytes, gathering around the nucleus [61]; (3) κ-specific opioid
binding sites, besides being expressed on ESC plasma membranes [60], could also be identified in ESC
nuclei, with a single dissociation constant in the low-nanomolar range [61]; (4) a significant increase in
the maximal binding capacity (Bmax) for a selective κ-opioid receptor ligand was detected in nuclei
that had been isolated from ESC-derived cardiomyocytes, compared with nuclei from undifferentiated
cells [61]. On this basis, we were further encouraged to understand whether the presence of nuclear
endorphin receptors in ESCs may have represented the interface for a causative intracrine patterning
in cardiogenesis. This hypothesis was confirmed by the finding that direct exposure to dynorphin B or
U-50,488H, a synthetic κ-opioid receptor agonist, of nuclei isolated from undifferentiated ESCs was able
to induce time- and dose-dependent increase in the transcription rate of both GATA-4 and Nkx-2.5 [61].
The incubation of ESC nuclei in the presence of dynorphin B also enhanced the rate of transcription of
the prodynorphin gene, further highlighting the capability of this intracrine endorphinergic system to
operate in a feed-forward fashion to upregulate its own synthesis or boost elements of its signaling
cascade [61]. To this end, the intracrine action of dynorphin B on its nuclear receptors proved to be
specific in nature, since besides being blocked by naloxone, a broad opioid receptor antagonist, it was
also abrogated by Nor-binaltorphimine and Mr-1452, two selective κ-opioid receptor antagonists [61].
In this study, the observation that both Mr-1453 and (+) naloxone, two inactive enantiomers, failed
to affect the transcriptional responses induced by dynorphin B, proved that its intracrine modality
was exploited in a stereospecific fashion on the identified nuclear opioid receptors. The finding that
exposure of ESC nuclei to dynorphin B failed to affect the transcription of both MyoD and neurogenin-1,
involved in skeletal myogenesis and neurogenesis, respectively, provides evidence that the intracrine
action of dynorphin B retained an extremely high degree of selectivity, being essentially oriented to a
cardiogenic decision [61]. In the attempt of elucidating the signaling pathways triggered by intracrine
dynorphin B, we started from our previous studies showing that PKC signaling was able to transduce
the cardiogenesis primed by endogenous dynorphin B in ESCs, and that cardiac differentiation was
associated with nuclear translocation of PKC-α, -β1, and -β2, while the expression of PKC-δ and -ε
was mainly restricted to ESC nuclei [24]. Both PKC-δ and -ε resulted in being overexpressed in nuclei
of ESC-derived cardiomyocytes, and their increase occurred independently of translocation, likely as a
consequence of changes in isozyme (PKC-δ and -ε) turnover and/or gene expression. While κ-opioid
receptor antagonists, acting on plasma membrane opioid receptors, prevented the nuclear translocation
of PKC-α, -β1, and -β2, they failed to affect the nuclear increase in PKC-δ and -ε [61]. Notably,
opioid receptor antagonism, by interfering with the autocrine loop mediated by secreted dynorphin
B, reduced, but did not abolish the yield of spontaneously beating ESC-derived cardiomyocytes,
indicating that an additional mechanism of cardiogenesis may have been occurred. The observation
that cell permeant PKC inhibitors conversely caused a complete abrogation of cardiogenesis led us to
investigate whether nuclear resident PKC isoforms, namely -δ, and -ε, may represent the missing circuit
in the intracrine signaling cascade, linking the stimulation of nuclear opioid receptors to the observed
transcription of cardiogenic genes. Confirming this hypothesis, nuclei isolated from undifferentiated
ESCs were able to phosphorylate the acrylodan-labeled MARCKS peptide, a high-affinity fluorescent
PKC substrate. Exposure of these nuclei to dynorphin B was able to induce a remarkable increase in
nuclear PKC activity, which was suppressed by opioid receptor antagonists [61]. Worthy to note, PKC
inhibitors not only suppressed the nuclear PKC activity, but abolished the transcriptional responses
primed by dynorphin B in isolated nuclei (i.e., the induction of GATA-4, Nkx-2.5, and prodynorphin
gene transcription) [61]. These findings, considered together with the observation that the same PKC
inhibitors were able to abrogate the cardiac differentiation in ESCs, further supported the evidence that
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dynorphin B plays a major role in ESC cardiogenesis, and that nuclear opioid receptors and nuclear
PKC were coupled to stem cell cardiac differentiation through the execution of an intracrine circuitry
(Figure 3).
Figure 3. Intracrine dynorphin B pathway in embryonic stem cells (ESCs). The figure represents a
virtual ES cell where different experimental evidence (detailed in the manuscript) is shown. MHC:
α-Myosin heavy chain; MLC: Myosin light chain; SA: α-sarcomeric actinin.
At the time of our discovery of nuclear endorphinergic pathways regulating prodynorphin and
cardiogenic gene transcription, we hypothesized that newly synthesized dynorphin B or a partial
amount of it, may react with opioid receptors in the perinuclear space, without being secreted
extracellularly. Through the years, it has become evident that a consistent number of small peptides
do not exert their effects as naked molecules, but they are trafficking among cells via an exosomal
route. This may imply that a part of dynorphin B, packaged within exosomes, once secreted may use
exosomes to enter the cells, then acting via an intracrine pathway following internalization. Detailed
investigation of these issues is still lacking, and further studies are needed to elucidate whether
exosomal trafficking of dynorphin B and other endorphin peptides may significantly take place and
affect cellular dynamics.
The cardiogenic effect of dynorphin B has been recently confirmed in mice cardiac progenitor cells
(CPCs), an Nkx-2.5 expressing cell population detectable in mid-gestation (E 11.5) mouse ventricles [62].
CPCs have fewer mitochondria than cardiomyocytes, and could be efficiently fractionated by the aid of
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a fluorescent dye targeting mitochondrial membrane potential, being separated by the cardiomyocyte
population containing a greater number of mitochondria [62]. Despite the expression of Nkx-2.5,
only a low fraction (about 1%) of the low-mitochondria CPCs can be positively stained with MF20,
recognizing the expression of α-MHC. Exposure of CPCs to dynorphin B caused a remarkable increase
in the number of CPC-derived cardiomyocytes [62], while exposure to the conditioned medium yielded
from high-mitochondria fraction of cardiac myocytes resulted in significant inhibition of cardiogenesis,
suggesting a paracrine inhibitory role of adult cardiomyocytes over the cardiogenic potential of
CPCs [62]. Further studies are required to investigate the potential contribution of an intracrine
pathway in the cardiogenesis induced by dynorphin B in CPCs. Dissecting the relative contribution
of intracrine and paracrine/autocrine pathways in CPCs subjected to the treatment with dynorphin
B alone, or in combination with other cardiac lineage promoting agents, may prove rewarding in
optimizing the cardiogenic potential of CPCs and their engraftment efficiency in experimental models
of acute myocardial infarction or chronic heart failure.
On the whole, the above-reported observation should be taken into account when dissecting the
implications that may arise from the use of dynorphin B knockout animals. In fact, initially established
homozygous mutant mice lacking dynorphin B did not show any apparent impairment, compared
to heterozygous and wild type littermates with respect to cage behavior, growth, weight, fertility,
and longevity [63]. Nevertheless, subsequent investigation revealed that κ opioid receptor null mice
suffered for altered bone morphogenesis [64], and accelerated cartilage degeneration after injury [65],
in comparison to wild type animals, and that the associated defects could be efficiently rescued by κ
opioid receptor activation [64,65]. Moreover, κ opioid receptor-null or dynorphin-null mice revealed a
pronounced enhancement in overall vascular formation, associated with ectopic vascular invasion into
somites at day 10.5 of embryonic development [66], indicating that dynorphin B knockout could also
be used to unveil regulation of endothelial cell differentiation and pathfinding in vascular development
by a κ opioid receptor system. These reports, together with other results providing wide-ranging
regulation of metabolic and adaptive responses by dynorphinergic systems in dynorphin B knockout
mice [67,68], suggest that given the complexity of heart development and of the associated process
of cardiomyogenesis, further, more accurate studies are needed to explore the effect of dynorphin
B and/or κ opioid receptor knockout on the expression of the cardiac lineage potential in targeted
subset of stem cells, including CPCs. Addressing these issues may provide further insights into the
potential involvement of paracrine/autocrine or intracrine patterning to explain the initial observation
that high-level of endorphin gene expression could be detected in post-natal rat hearts [49,50], and that
exposure to the opioid antagonist naltrexone throughout gestation was able to alter postnatal heart
development [69], while dynorphin B administered to newborn rats was found to modulate heart
morphogenesis [70].
3. Hyaluronan Mixed Esters of Butyric and Retinoic Acids (HBR): A Synthetic Intracrine
Promoting Prodynorphin Gene and Dynorphin B Expression, Stem Cell Cardiogenesis and
Cardiac Repair
Dynorphin B, like other endorphins, is an easily degradable, short-lived peptide, subjected
to rapid inactivation by natural metallo-endopeptidases and aminopeptidases. An ideal strategy
to afford a long-lasting intracellular availability of dynorphin peptides and sustain their intracrine
action should, therefore, rely upon increasing the transcription of the prodynorphin gene, possibly
without resorting to complex approaches of viral vector-mediated gene transfer technology. Within
this context, we have developed HBR, with the aim of making available a synthetic cardiac/vascular
lineage-promoting agent [71]. Consistent observations provided a rationale behind the development
of HBR. The hyaluronan CD44 receptor is remarkably expressed by cardiac progenitors [72], and
normal cardiogenesis can be suppressed by chemical inhibition of type-2 hyaluronan synthase [73].
Hyaluronan primes CD44-dependent endothelial cell differentiation [74], and CD44 plays a relevant
role in vasculogenesis [75]. Hyaluronan can enter the cell through CD44 receptor-mediated endocytosis,
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and it has been found in close association with nuclear heterochromatin [76]. Hyaluronan-binding
molecules (hyaladherins) can translocate to the nucleus upon mitogenic stimulation [77], serving as
docking and activators for protein kinases and transcription factors that promote cellular growth and
differentiation [78]. Therefore, we hypothesized that, while being taken up by the stem cells, hyaluronan
could also be exploited as a carrier for the internalization of hyaluronan-grafted molecules essential
in the cardiogenic process, such as butyric and retinoic acids. Butyric acid is capable of increasing
transcription factor accessibility to targeted DNA regulatory sites, owing to histone deacetylase
inhibition, and consequent hyperacetylation of nucleosomal histones [79]. Accordingly, in mouse
ESCs, inhibition of histone deacetylase and shear stress-induced histone acetylation has been shown to
elicit epigenetic patterns responsible for the activation of transcriptional signatures of cardiovascular
commitment [80]. Concerning retinoic acid, its role in cardiovascular commitment is supported by the
observation that abnormal cardiogenesis results from inactivation of the RXRα gene transcription, and
from the combination of mouse strains with mutant RAR and RXR subtypes [81,82]. Moreover, the
efficiency of cardiogenesis can be increased in ESCs by all-trans and 9-cis-retinoic acids [83]. Retinoic
acid is also required in vasculogenesis in vivo [84], is essential in mammalian vascular development.
When assessed in mouse ESCs, HBR induced overexpression of the prodynorphin gene, together
with an increase in GATA-4 and Nkx-2.5 transcription [71]. These transcriptional responses were
already evident at the stage in which cells were grown as embryoid bodies in suspension and persisted
in ESC-derived cardiomyocytes. Since from the early stage of HBR induced cardiac commitment,
the intracellular level of dynorphin B was remarkably increased, suggesting the activation of an
intracrine route of cardiogenesis [71]. In HBR treated cells, the intracellular amount of dynorphin B
further increased throughout the acquirement of a terminally differentiated state, with a remarkably
greater number of spontaneously beating myocardial cells, as compared to the untreated controls. The
observed increase of intracellular dynorphin B in HBR exposed ESCs was paralleled by a consistent
raise of peptide levels in the culture medium [71]. This observation suggests that secreted dynorphin B
may also have enhanced the cardiogenic yield through the establishment of an autocrine mechanism,
as it was previously shown to occur in the course of the spontaneous ESC cardiogenesis [60]. The
cardiogenic/vasculogenic action observed with HBR in ESCs, could also be exploited in human
mesenchymal stem cells (hMSCs) isolated from different sources, including the bone marrow, dental
pulp, and fetal membranes of term placenta (FMhMSCs) [85]. In these cells, HBR enhanced VEGF,
kinase insert domain receptor (KDR, a gene encoding a major VEGF receptor), and hepatocyte growth
factor (HGF) gene expression, as well as the secretion of the angiogenic, mitogenic, and antiapoptotic
factors VEGF and HGF, priming stem cell differentiation into endothelial cells [85]. Confirming the
results yielded in ESCs, in multisource hMSCs, HBR increased both the transcription of GATA-4 and
Nkx-2.5, and the yield of cardiac marker-expressing cells [85]. These responses were notably more
pronounced in FMhMSCs.
The fact the HBR was not able to affect the commitment of mouse ESCs towards skeletal myogenesis
or neurogenesis, indicates that the effect of the mixed esters was rather specific in nature or that it did
not simply enhance the overall differentiating ESC potential [71]. This view is further corroborated by
a number of observations, showing that: (1) In mouse ESCs, the transcription of GATA-4, Nkx-2.5, and
that of the prodynorphin gene itself not only was increased by HBR at the level of embryoid bodies, but
they were also enhanced in puromycin-selected ESC-derived cardiomyocytes [71]; (2) the mixed ester
proved effective in increasing the gene expression of the two cardiac-specific markers α-MHC and
MLC-2V in puromycin selected cells [71]; (3) it enhanced the yield of MHC-positive cells together with
the yield of spontaneously beating cardiomyocytes [71]; (4) HBR increased the yield of ESC-derived
cardiomyocytes at a substantially higher level than the monoesters of hyaluronan with butyric (HB) or
retinoic acids (HR) [71]; (5) in multi-source hMSCs, including those that had been isolated from the
bone marrow, the dental pulp and term placenta, HBR lack any effect on MyoD gene transcription, a
major conductor of skeletal myogenesis [85], and neurogenin 1, a neurogenic transcription factor [86].
Nevertheless, the observation that the transcriptional responses elicited by HBR in hMSCs affected
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genes involved in vasculogenic/angiogenic pathways [85], indicates that the action of the mixed ester
besides involving the prodynorphin gene, encompassed a modulation of other genes playing a pivotal
role in the cardiovascular system.
The cardiogenic/vasculogenic effects induced in vitro on stem cells by HBR, could also be deployed
in vivo, to afford efficient strategies of cardiac regeneration. In both small (rats) [85], and large
animal models (pigs) of acute myocardial infarction [87], the transplantation of HBR-preconditioned
FMhMSCs enhanced myocardial vascularization and contractility, while reducing the infarct scar size,
at a significantly greater extent, as compared to the transplantation of untreated FMhMSCs [87].
Intriguingly, by the aid of magnetic resonance imaging, positron emission tomography, and
immunohistochemistry, we have shown that the injection of HBR itself into infarcted rat hearts
afforded a substantial cardiovascular repair, reducing the infarct size and affording a full recovery of
myocardial performance, without the needs for stem cell transplantation [88]. HBR restored cardiac
[18F] fluorodeoxyglucose uptake, increased capillary density, and decreased the number of apoptotic
cardiomyocytes, recruiting endogenous Stro-1-positive stem cells at the infarct border zone [88]. The
possibility that HBR may have acted as a synthetic intracrine in the rescue of damaged myocardium is
supported by multiple layers of evidence: (1) Nuclear run-off transcription assays revealed that the
transcription of GATA-4, Nkx-2.5 (two cardiogenic genes) and HGF (a vasculogenic gene) was enhanced
in nuclei that had been isolated from HBR treated hMSCs, as compared with nuclei from untreated
cells [88]; (2) similarly, the transcription of VEGF (another vasculogenic gene) and Pim-1 (a pro-survival
gene) were increased in nuclei obtained from HBR exposed Stro-1 positive stem cells [88]; (3) nuclear
run-off experiments showed that the transcription of the above-mentioned genes was not affected
by direct exposure to HBR of nuclei isolated from undifferentiated ESCs or hMSCs. On the contrary,
the transcription rate of the same genes was increased with superimposable time courses by nuclear
exposure to butyric or retinoic acids and was additively enhanced by a mixture of the two [88–90]. These
findings suggest that after internalization HBR may have been subjected to hydrolysis by ubiquitous
intracellular esterases, unfolding an intracrine action of its own grafted moieties. In both ESCs and
hMSCs, HBR differentially affected the patterning of Smad proteins, acting as major conductors in
cardiogenesis, enhancing the gene and protein expression of Smad1, 3, and 4, while downregulating
Smad7, with increased transcription rates of Smad4 in nuclei isolated from HBR treated cells [89].
Within this context, an intracrine pathway for HBR was supported by the observation that Smad4
binding to the Nkx-2.5 gene resulted in being crucial for HBR mediated cardiogenesis. Chromatin
immuno-precipitation experiments showed that nuclear extracts from control and HBR-treated ESCs
generated an amplified product for the Smad binding element on the Nkx-2.5 promoter, and that a
significantly higher amount of amplified DNA could be generated from nuclei isolated from HBR
treated ESCs, as compared with nuclei of unexposed cells [89]. Compounding the intracrine action
of HBR, the injection of the mixed ester in the infarcted rat myocardium increased tissue histone H4
acetylation at the level of myocardial nuclei [88]. This result was mirrored by the observation that
acetyl-H4 immunoreactivity was also enhanced at the nuclear level in rat cardiomyocytes and Stro-1
cells exposed to HBR [88] (Table 2). Thus, HBR, a molecule boosting a gene program of cardiogenic and
vasculogenic commitment in vitro and in vivo, proved to be itself acting at least in part as an intracrine
regulator in the same differentiating/rescuing programs.
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Table 2. Hyaluronan mixed esters of butyric and retinoic acids (HBR) studies for cardiac commitment
and repair.
Stimulus Species Cell Type Biological Effects Ref.
HBR1 0.75 mg/mL
for five days of
treatment
Mouse ESCs
Overexpression of the prodynorphin
gene
Increase in GATA-4 and Nkx-2.5
transcription
Increase of dynorphin B at the
intracellular level and in the culture
medium
Increase of the number of
spontaneously beating myocardial
cells
Expression of α-MHC and MLC-2V in
spontaneously beating
cardiomyocytes
Absence of effect on skeletal
myogenic or neurogenic markers
[71]













Improvement of VEGF3, KDR4, and
HGF5 gene expression
Increase of VEGF and HGF secretion
Increase in GATA-4 and Nkx-2.5
transcription
Expression of cardiac markers
Absence of effect on skeletal










Rat and Pig Cardiomyocytes
Enhancement of myocardial
vascularization and contractility
Reduction of the infarct scar size
[85,87]
HBR injection (0.2






Presence of cardiovascular repair,
reducing the infarct size and affording
a full recovery of myocardial
performance
Increase of capillary density, and
decrease of the number of apoptotic
cardiomyocytes
Increase of histone H4 acetylation at
the level of myocardial nuclei
[88]
HBR 2 mg/mL
(from 1 to 10 days
of treatment) Human MSCs
Enhancement of Smad1, 3, and 4 gene
and protein expression
Downregulation of Smad7
Increase of transcription rates of
Smad4 in nuclei isolated from HBR
treated cells correlated to Nkx-2.5
expression
[89,90]
1 Hyaluronan mixed esters of butyric and retinoic acids; 2 mesenchymal stem cells; 3 vascular endothelial growth
factor; 4 kinase insert domain receptor; 5 hepatocyte growth factor; 6 fetal membranes of term placenta.
4. The Use of Electromagnetic Energy to Afford Efficient Increase in Prodynorphin Gene and
Dynorphin B Expression. Implications in Myocardial Cell Growth and Stem Cell Cardiogenesis
Magnetic fields (MF) have long been shown to promote behavioral changes in vivo, and modulate
cell proliferation and growth factor release in vitro [91–93]. Since from these initial studies, the
endogenous opioid peptide network emerged among the biological systems that may represent a target
for MF, as revealed by the evidence that: (1) In in vivo animal models MF is able to induce analgesic
effects through an opioid-mediated mechanism [94]; (2) MF can affect the spontaneous electrical
activity in the brain by interfering with the action of both endogenous, or exogenously administered
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opioids [95]; (3) MF increase the duration of opioid-induced anesthesia in mice [96]; (4) opioid receptor
subtypes were found to mediate MF-induced decrease in central cholinergic activity in the rat [97];
(5) the effect of MF on central cholinergic systems could be blocked by the opioid receptor antagonist
naltrexone [98]; (6) the same antagonist was also able to antagonize the antiparkinsonian effects of
picotesla range MF [99].
Nevertheless, during the period, these findings were gathered, compelling evidence that
MF may affect transcriptional responses was still lacking. Based upon our observation that a
dynorphinergic system was involved in cardiac contractility and cardiogenesis, and taking into account
the above-reported relevance of endogenous opioids as a target biological system for MF, we decided
to investigate whether this form of physical energy could be able to influence opioid peptide gene
expression in adult myocardial cells. By the aid of RNAse protection analyses, we provided evidence
that extremely-low frequency MF (ELF-MF) of 50 Hz, 0.8 mTrsm consistently increased prodynorphin
mRNA levels as early as after 1 h of exposure. The stimulatory effect peaked at 4 h and was still evident
after 8 h of treatment [100]. Nuclear run-off transcription experiments revealed that prodynorphin
gene transcription was increased in nuclei that had been isolated from MF exposed cardiomyocytes.
Interestingly a direct exposure to ELF-MF of nuclei isolated from rat ventricular cardiac myocytes
caused a transcriptional increase in the prodynorphin gene of similar magnitude as that observed in
nuclei from exposed myocardial cells [100]. These observations proved that the MF-induced increase
in prodynorphin gene expression was caused by a direct action on the transcriptional machinery of
the nucleus, and it was not merely resulting from changes in mRNA stability or degradation. The
ELF-MF action was mediated by nuclear PKC activation, but occurred independently from changes
in PKC isozyme expression and enzyme translocation [100]. ELF-MF also markedly increased the
intracellular levels of dynorphin B, and enhanced its secretion in the culture medium [100]. These
findings for the first time demonstrated that an opioid gene was activated by cardiomyocyte exposure
to electromagnetic energy and that the cell nucleus and nuclear embedded PKC were a crucial target
for the ELF-MF action. We had previously shown that endorphin peptides exerted profound effects
on the phosphoinositide turnover in the myocardial cells, controlling cytosolic Ca2+ homeostasis
in both cardiac myocytes and neurons, also modulating cardiac intracellular pH and myofilament
responsiveness to Ca2+ [41–43]. Whether the raise of intracellular dynorphin B elicited by ELF-MF may
affect these determinants of myocardial cell function has remained so far as a suggestive hypothesis,
and at the same time an intriguing challenge, owing to the complexity of the experimental design
needed to address this issue.
In the subsequent investigation, we first found that exposure of mouse ESCs to ELF-MF of
50 Hz, 0.8 mTRSM, triggered the expression of GATA-4 and Nkx-2.5, leading to a consistent increase
in the number of spontaneously beating ESC-derived cardiomyocytes, as compared with unexposed
cells [101]. Such cardiogenic effect was associated with enhanced prodynorphin gene expression. RNase
protection analyses and nuclear run-off experiments provided evidence that the ELF-MF effect was
afforded by an increase of the transcription rate of the prodynorphin gene in isolated nuclei, raising the
intracellular levels of dynorphin B [101]. Similar to spontaneous ESC cardiogenesis, the increase in
prodynorphin gene transcription was also associated with an increase in dynorphin B secretion in the
culture medium [101]. These findings indicate that ESC exposure to electromagnetic energy was able
to activate a complex circuitry linking prodynorphin gene transcription and cardiogenesis through the
intracrine/autocrine signaling of a bioactive product of the gene itself.
It may be worthy to note that with the investigated type of ELF-MF we only obtained a
cardiogenic commitment from the exposed ESCs, without significant differentiating outcomes towards
non-myocardial lineages [101]; thus, ruling out the possibility that the observed cardiogenic action
may simply be part of a broader, generalized transcriptional response, or it may be resulting from
non-specific changes in protein degradation.
More recently, we used a different exposure technology to convey MF to both mouse ESCs and
hMSCs, based upon cell stimulation with a radiofrequency of 2.4 GHz emitted by a radioelectric
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asymmetric conveyer (REAC) [102]. The REAC technology has the innovative feature of generating an
extremely weak microwave emission, being effective at emitter power levels as low as approximately
2 mW. The REAC action is independent of the radiofrequency emission used. We used only the
frequencies of 2.4 and 5.8 GHz, the most widespread and authorized worldwide (i.e., Wi-Fi). The
particular physic connection between the apparatus and the cell culture or patient’s tissues, rather
than emitted radiofrequency, represents the hallmark of the REAC technology. Such a connection is
afforded via the asymmetric conveyer probe [102,103]. This probe is, therefore, a part of an innovative
method and device enabling the emitted frequency to interact without depth limits with cultured
cells in vitro or with the body tissues in vivo. Within the biological target, this interaction elicits
radiofrequency-induced microcurrents, varying on the bases to the molecular features of targeted tissues
or cells. Merging of such radiofrequency-induced microcurrents ensues in a resulting microcurrent,
generated by the target itself. This resulting microcurrent, concentrated by the asymmetric conveyer
probe, appears to be responsible for the observed biological responses and therapeutic effects [103,104].
With the REAC technology, we succeeded in optimizing pluripotency and multipotency in mouse ESCs
and hMSCs isolated from the adipose tissue (AD-hMSCs), respectively, modulating the transcription
of stemness genes and increasing the yield of cells differentiating into cardiac, neural, skeletal and
myogenic lineages [102,105]. These findings indicate that changing the MF frequency and the modality
of MF interaction with the target cells would result in a broader spectrum of transcriptional responses
and in a multilineage commitment of the exposed stem cells. While the activation of neurogenesis
and skeletal myogenesis involved the overexpression of neurogenin-1 and MyoD, respectively, the
enhancement of GATA-4 and Nkx-2.5 elicited by REAC during the cardiogenic commitment of both
ESCs and adult stem cells was still associated with an increase in prodynorphin gene transcription, as it
was observed following ESC exposure to ELF-MF [102,105].
These observations indicate that, while the transcriptional responses primed by REAC were
placed within a wider context of cell signaling networks, the cardiogenic counterpart of the REAC
action retained similar features as those that were uniquely elicited by ELF-MF (which did not affect
ESC commitment outside of a cardiogenic pathway) [101]. Moreover, the results yielded following
stem cell exposure to the REAC technology, further confirmed the cardiogenic role of the prodynorphin
gene, and the feasibility of using a physical stimulation to activate an endorphinergic system and its
related signaling, even within a frame of enhanced pluri-/multi-potency expression. This view was
further inferred from intriguing results showing that the exposure to REAC-conveyed radioelectric
fields afforded a remarkable commitment toward cardiac, neuronal, and skeletal muscle lineages even
in human skin fibroblasts [106]. The REAC action was associated with a biphasic effect on a number of
stemness-related genes, leading to an early transcriptional increase of Oct4, Sox2, c-Myc, Nanog, and
Klf4 within 6–20 h, followed by downregulation at later times [106]. This observation indicates that the
REAC action bypassed a persistent reprogramming toward an induced pluripotent stem cell-like state,
avoiding the extremely low differentiation efficiency and the risk of tumorigenic drift associated with
cell reprogramming with viral vector-mediated approaches. The increase in MyoD and neurogenin-1
transcription observed during the skeletal myogenesis and neurogenesis elicited by REAC led to the
expression of the corresponding tissue-restricted marker proteins, MyoD and β3-tubulin, as assessed
by confocal microscopy analysis [106]. The transformation of human skin fibroblasts into cardiac-like
cells expressing α-MHC and SA, was again mediated by the transcriptional activation of a cardiogenic
program, encompassing a consistent increase in the transcription of the prodynorphin gene, together
with the overexpression of other remarkable cardiogenic transcripts, including Mef2c, Tbx5, GATA-4,
and Nkx-2.5 [106]. These findings also showed for the first time the chance of using physical energy to
frame the activation of a conductor of cardiogenesis, like the prodynorphin gene, within the context of a
pluripotentiality expression in human adult somatic cells (Table 3). Compounding the spectrum of the
biological actions of the REAC technology, we found that it was able to counteract and even reverse
stem cell aging through the rescue of both telomerase-dependent and -independent pathways [107–109].
These effects involved a substantial contribution from intracrine hyaluronan-related mechanisms, since
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the chemical abrogation of endogenous type-2 hyaluronan synthase remarkably counteracted the
antiaging effect of REAC [110]. Whether the intracellular hyaluronan signaling may also encompass
the deployment of intracrine endorphinergic paths remains to be established, and it is the subject for
our ongoing investigation.
Table 3. Magnetic fields (MF) studies and cardiac commitment.
Stimulus Species Cell Type Biological Effects Ref.
ELF-MF1 of 50 Hz,
0.8 mTRSM







Increase in prodynorphin gene
transcription
Increase in intracellular levels of
dynorphin B
Enhancement in dynorphin B
secretion in the culture medium
[100]
ELF-MF of 50 Hz,
0.8 mTRSM(for
three and ten days
of treatment)
mouse ESCs
Induction of GATA-4 and Nkx-2.5
gene expression
Increase in the number of
spontaneously beating
ESC-derived cardiomyocytes
Increase in the transcription rate
of the prodynorphin gene
Increase in intracellular levels of
dynorphin B
Enhancement in dynorphin B
secretion in the culture medium
[101]
Radiofrequency of




mouse and human ESCs andAD-MSCs
Modulation in the transcription of
stemness genes
Increase in the yield of cells
differentiating into cardiac, neural,
skeletal and myogenic lineages
Association of cardiac
differentiation with GATA-4,




2.4 GHz emitted by
REAC
(from 2 to 72 h of
treatment and 72 h
of treatment + four
or seven days of
recovery)
human Dermal skinfibroblasts
Early transcriptional increase of
Oct4, Sox2, c-Myc, Nanog, and Klf4,
stemness genes followed by their
downregulation
Increase in the yield of cells
differentiating into cardiac, neural
and myogenic lineages
Association of cardiac
differentiation with: Expression of
Mef2c, Tbx5, GATA-4 and Nkx-2.5
genes; expression of MHC and SA
proteins; increase in the
expression of prodynorphin gene
[106]
1 extremely-low frequency magnetic fields; 2 radioelectric asymmetric conveyer.
5. Conclusions and Future Perspective
Collectively, the findings reported here show the participation of dynorphin-mediated intracrine
positive feedback loops in the differentiation of stem cells along a cardiac lineage and further suggest
that dynorphin signaling interacts with targeted transcription factors, possibly through the upregulation
of other intracrine loops. For example, the recruitment of Nkx-2.5 and GATA-4 raises the possibility
that they too could behave in an intracrine fashion. Feed-forward mechanisms are executed through
the ability of dynorphin B of acting on its coupled receptor and signaling in isolated nuclei to stimulate
the transcription of its own coding gene, as well as the transcription of homeodomain and zinc-finger
transcription factors. Analysis of these circuitries suggests the establishment of a positive feedback loop,
intervening in the timely amplification and synchronization of multiple intracrinergic systems, since
transcription factors, including zinc-fingers and the homeodomains, have been found to be exchanged
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among cells through the exosomal route and act intracellularly after internalization, fulfilling the pattern
requirement for being considered as intracrines. The intracrine involvement in stem cell commitment
prompts the use of intracrine peptides for reprogramming (stem) cells to a pluripotency state, thereby
obviating the needs for viral transfection and possible secondary neoplastic transformation. Indeed, it
is becoming clear that the therapeutic effects elicited by stem cells are multifaceted, and, in large part,
they result from actions other than their proliferation and direct differentiation into cells composing the
adult tissues. Among these other actions of tissue stem cells is included the elaboration of a variety of
cytokines and growth factors. The possibility of intracrine patterning played by these trophic mediators
in modulating the fate of stem cells and their rescuing potential appears to be worthy of exploration.
We are currently becoming aware of the fact that exposure to physical energies, like MF of different
frequencies and modalities of conveying, and possibly other physical stimuli, including mechanical
vibration and light, can be exploited to variably modulate the transcription of genes essential in crucial
fate decisions of stem cells. This approach may offer the chance of controlling intracrine pathways
in a precise way without the use of viral vector-mediated tools or cumbersome chemistry, not only
in vitro, but even in vivo. In fact, based upon the diffusive features of these physical energies, we are
envisioning the perspective of targeting human stem cells in place, where they already are, resident
in all the tissues of the human body, affording the modulation of multifaceted pathways, as those
controlled by intracrine molecules, without the need of stem cell or tissue transplantation, boosting
our inherent self-healing ability.
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Abbreviations
ACE Angiotensin Converting Enzyme
AD Adipose tissue
CPCs Cardiac progenitor cells
DMSO Dimethyl sulfoxide
ELF-MF Extremely-low frequency magnetic fields
ESCs Embryonic stem cells
FGF1 Fibroblast growth factor 1
FM Fetal membranes
HBR Hyaluronan mixed esters of butyric and retinoic acids
HEL Human erythroleukemia cells
HGF Hepatocyte growth factor
hMSCs Human mesenchymal stem cells




KDR Kinase insert domain receptor
MF Magnetic fields
MHC Myosin heavy chain
MKs megakaryocytes
MLC Myosin light chain
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PKC Protein kinase C
PMA Phorbol 12-myristate 13-acetate
REAC Radioelectric asymmetric conveyer
SA Sarcomeric actinin
VEGF Vascular endothelial growth factor
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